ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 60 filers reported holding ESSA PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25 | +13.6% | 8 | 0.0% | 0.00% | – |
| Q2 2023 | $22 | -99.7% | 8 | -99.6% | 0.00% | – |
| Q1 2023 | $6,445 | +152.3% | 2,170 | +114.0% | 0.00% | – |
| Q4 2022 | $2,555 | – | 1,014 | +12575.0% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 8 | -99.9% | 0.00% | – |
| Q2 2022 | $27,000 | -62.5% | 8,664 | -25.4% | 0.00% | – |
| Q1 2022 | $72,000 | -37.9% | 11,614 | +41.7% | 0.00% | – |
| Q4 2021 | $116,000 | +110.9% | 8,194 | +18.1% | 0.00% | – |
| Q3 2021 | $55,000 | -52.2% | 6,936 | +72.6% | 0.00% | – |
| Q2 2021 | $115,000 | +379.2% | 4,019 | +390.1% | 0.00% | – |
| Q1 2021 | $24,000 | – | 820 | +10150.0% | 0.00% | – |
| Q4 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 8 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,223,799 | $26,103,000 | 3.37% |
| MPM BioImpact LLC | 660,892 | $4,084,000 | 1.10% |
| BVF INC/IL | 3,695,629 | $22,839,000 | 0.91% |
| Omega Fund Management, LLC | 328,196 | $2,028,000 | 0.42% |
| Eventide Asset Management | 4,170,259 | $25,772,000 | 0.40% |
| Frazier Life Sciences Management, L.P. | 692,910 | $4,282,000 | 0.36% |
| Bellevue Group AG | 5,034,814 | $31,115,000 | 0.36% |
| RTW INVESTMENTS, LP | 2,637,192 | $16,298,000 | 0.34% |
| Avidity Partners Management LP | 2,460,000 | $15,203,000 | 0.32% |
| Rhenman & Partners Asset Management AB | 410,923 | $2,540,000 | 0.25% |